XL281
- Generic Name
- XL281
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
XL281 is a novel anticancer compound designed to potently inhibit the RAS/RAF/MEK/ERK signaling pathway. Mutational activation of RAS occurs in about 30 percent of all human tumors, including non-small cell lung, pancreatic, and colon cancer. XL281 is a specific inhibitor of RAF kinases, including the mutant form of B-RAF, which is activated in 60 percent of...
- Indication
Investigated for use/treatment in solid tumors.
- Associated Conditions
- -
- Associated Therapies
- -
Study of XL281 in Adults With Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2007-03-26
- Last Posted Date
- 2011-10-13
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 180
- Registration Number
- NCT00451880
- Locations
- 🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
🇺🇸Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.